Ensysce Biosciences (ENSC)
NASDAQ:ENSC
Want to see ENSC full AI Analyst Report?
ENSC Stock Chart & Stats
$1.01
-$0.28(-3.41%)
At close: 4:00 PM EST
$1.01
-$0.28(-3.41%)
Day’s Range― - ―
52-Week Range$0.31 - $4.85
Previous CloseN/A
Volume52.20K
Average Volume (3M)89.63K
Market Cap
$4.96M
Enterprise Value-$4.00T
Total Cash (Recent Filing)$4.31T
Total Debt (Recent Filing)$306.71B
Price to Earnings (P/E)―
Beta1.70
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding9,277,819
10 Day Avg. Volume106,568
30 Day Avg. Volume89,627
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)<0.01
Price to Sales (P/S)0.46
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-806.44K
Enterprise Value/Revenue-790.19K
Enterprise Value/Gross Profit2.36M
Enterprise Value/Ebitda854.34K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$2.50M
Bulls Say, Bears Say
Bulls Say
Proprietary Abuse-deterrent TechnologiesEnsysce’s TAAP and MPAR platforms are proprietary technical barriers that differentiate its pipeline in opioid analgesics. These durable IP-based advantages increase partnership and licensing appeal, improve long-term commercialization prospects if clinical success is achieved, and address regulatory focus on abuse reduction.
Near-term Committed Financing LineA committed funding line with an initial $2M tranche and potential access to more capital over 24 months materially extends the development runway. This structural liquidity reduces immediate financing stress, enabling planned clinical work and milestone delivery that support durable program advancement and partnership negotiations.
Improved Leverage And Equity PositionTransition to positive equity and low debt provides greater financial flexibility than prior negative-equity years. This stronger balance sheet footing lowers default and covenant risk, enhances ability to negotiate strategic collaborations or structured financings, and supports continuity of R&D investment over the medium term.
Bears Say
Revenue Collapsed To ZeroThe near-absence of product revenue makes the business fully dependent on external financing and partnerships. Without recurring commercial income, Ensysce lacks a durable internal funding source, increasing execution risk: program delays or failed trials would quickly strain liquidity and hinder long-term sustainability.
Persistent Cash Burn And Negative Cash FlowOngoing negative operating and free cash flow erodes reserves and forces repeated capital raises. Sustained cash burn raises the probability of dilutive financings or curtailed R&D if markets tighten, creating structural pressure on program timelines, partner negotiations, and the company's ability to reach value-driving clinical milestones.
Dilutive Financing Structure & Governance TurnoverUse of convertible preferred and extensive warrants creates future share overhang and dilution risk, which can deter new equity investors and compress existing holders' long-term returns. Combined with a recent board resignation, governance disruption and capital structure complexity raise execution and oversight risks for strategic development.
Ensysce Biosciences News
ENSC FAQ
What was Ensysce Biosciences’s price range in the past 12 months?
Ensysce Biosciences lowest stock price was $0.31 and its highest was $4.85 in the past 12 months.
What is Ensysce Biosciences’s market cap?
Ensysce Biosciences’s market cap is $4.96M.
When is Ensysce Biosciences’s upcoming earnings report date?
Ensysce Biosciences’s upcoming earnings report date is May 18, 2026 which is in 29 days.
How were Ensysce Biosciences’s earnings last quarter?
Ensysce Biosciences released its earnings results on Mar 30, 2026. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$1.26 by $0.51.
Is Ensysce Biosciences overvalued?
According to Wall Street analysts Ensysce Biosciences’s price is currently Overvalued.
Does Ensysce Biosciences pay dividends?
Ensysce Biosciences does not currently pay dividends.
What is Ensysce Biosciences’s EPS estimate?
Ensysce Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ensysce Biosciences have?
Ensysce Biosciences has 9,277,819 shares outstanding.
What happened to Ensysce Biosciences’s price movement after its last earnings report?
Ensysce Biosciences reported an EPS of -$0.75 in its last earnings report, beating expectations of -$1.26. Following the earnings report the stock price went up 4.669%.
Which hedge fund is a major shareholder of Ensysce Biosciences?
Currently, no hedge funds are holding shares in ENSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ensysce Biosciences
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Technical Analysis
Ownership Overview
―
Insiders
0.62% Mutual Funds
11.38% Other Institutional Investors
87.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---